Ezra Aksoy, Queen Mary University of London, UK Updates Copyright 2016 Zietek and Rath
Ozempic is still the GLP-1 king, but Lilly is rapidly gaining market share, with its Q2 2024 sales reaching $3.01 billion compared to Novo Nordisks $5.38 billion
With over a decade of experience specializing in weight management, she champions personalized, sustainable, fun, and evidence-based nutrition solutions and behavior change coaching for patients on GLP-1 anti-obesity medications
GLP-1s appear to have a strong effect in reducing suicidal ideation and suicide attempts, as discussed below, both of which are common among SUD patients
However, in individuals with diabetes who are taking other glucose-lowering medications, the risk of hypoglycemia increases
Those with pre-existing deficiency, dietary restrictions, absorption issues, or multiple risk factors benefit from either adding b12 to their compounded semaglutide or taking it separately